Antivirals halve liver cancer risk in hep C
Antiviral drugs can halve the risk of developing liver cancer in people with chronic hepatitis C infection, research finds.
Just eight patients need to be treated to prevent one case of hepatocellular carcinoma over five years, a new systematic review and meta-analysis has concluded.
Including more than 2400 patients with chronic hepatitis C infection, it found those given antiviral therapy were 47% less likely to develop the cancer overall than those not treated.
Patients who successfully cleared the